The total number of records retrieved from this search are 63. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_856	Virus nameAdenovirus	Virus strainCV890	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1A and E1B gene under control of Adenovirus promoter	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Doxorubicin (10ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01pfu/cell	In-vitro result90% cancer cell killing after day 9, showing synergism with drug	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID11522637
IDOV_857	Virus nameAdenovirus	Virus strainCV890	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1A and E1B gene under control of Adenovirus promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01pfu/cell	In-vitro result35% cancer cell killing after day 9	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID11522637
IDOV_885	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result75% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_888	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.1 pfu/ml	In-vitro result95% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_891	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result70% cncer cell killing after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_894	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line3.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining and hematocytometer	In-vitro virus concentration0.01 pfu/ml	In-vitro result99% cncer cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID12788648
IDOV_1315	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro resultsome cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1316	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1317	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1318	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1319	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1320	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro resultsome cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1321	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1322	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1323	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1324	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1325	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.01 MOI	In-vitro resultsome cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1326	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1327	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1328	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1329	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cancer cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1360	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1361	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1362	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1363	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1364	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1365	Virus nameAdenovirus	Virus strainCNHK300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 MOI	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18300357
IDOV_1920	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1921	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1922	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1923	Virus nameAdenovirus	Virus strainSG600-IL24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding IL24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1932	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viabilty after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1933	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1934	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_1935	Virus nameAdenovirus	Virus strainSG600-EGFP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of gene encoding EGFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing EGFP gene	Source of cell lineInstitute of HCC, Fudan university	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result65% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce the apoptosis in HCC cell line	Immunogenic effectNA	Clinical trialNA	PMID20872968
IDOV_2531	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2532	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2533	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cellsa are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2541	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cells viable after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2542	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cells viable after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2543	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cells viable after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2544	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result60% cells viable after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2592	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cells are viable after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2593	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cells viavility	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2594	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2595	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2596	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2694	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2695	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2696	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2697	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2705	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CIK	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2706	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CIK	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_2707	Virus nameAdenovirus	Virus strainAdCN205-IL12	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with CIK	Immune gene insertion in viral genomeVirus expressing IL-12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssaySpectrophotometer	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23028626
IDOV_4276	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result3.8 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4425	Virus nameVesicular stomatitis virus	Virus strainRdB	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, no addition of linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration21:1 particle to pfu	In-vitro result70% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4433	Virus nameVesicular stomatitis virus	Virus strainRdB-1L-VSVG	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing VSVG epitope, with no dletion in HI-loop, addition of single linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHep3B	Concentration of cell line1.2E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration24:1 particle to pfu	In-vitro result30% cell survival after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26430798
IDOV_4877	Virus nameAdenovirus	Virus strainAd-deltaB	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma	Cell lineHep3B	Concentration of cell line70% confluence on 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination therapy and alone promotes apoptosis	Immunogenic effectActivation of caspase-3 and 8 and upregulation of IFN-gamma	Clinical trialNA	PMID27154307
IDOV_4878	Virus nameAdenovirus	Virus strainAd-deltaB	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma	Cell lineHep3B	Concentration of cell line70% confluence on 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination therapy and alone promotes apoptosis	Immunogenic effectActivation of caspase-3 and 8 and upregulation of IFN-gamma	Clinical trialNA	PMID27154307
IDOV_4879	Virus nameAdenovirus	Virus strainAd-deltaB	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationExpressing TRAIL and IL-12 gene in under CMV promoter in deleted E3 region of virus backbone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma	Cell lineHep3B	Concentration of cell line70% confluence on 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination therapy and alone promotes apoptosis	Immunogenic effectActivation of caspase-3 and 8 and upregulation of IFN-gamma	Clinical trialNA	PMID27154307
IDOV_4880	Virus nameAdenovirus	Virus strainAd-deltaB	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationExpressing TRAIL and IL-12 gene in under CMV promoter in deleted E3 region of virus backbone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL12 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma	Cell lineHep3B	Concentration of cell line70% confluence on 24 well plate	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombination therapy and alone promotes apoptosis	Immunogenic effectActivation of caspase-3 and 8 and upregulation of IFN-gamma	Clinical trialNA	PMID27154307
IDOV_5669	Virus nameAdenovirus	Virus strainOV802	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro resultComplete cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of IFN-Gamma, IL6 and other immunostimulatory cytokines production	Clinical trialNA	PMIDUS7473418
IDOV_5670	Virus nameAdenovirus	Virus strainOV802	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHep3B	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultComplete cancer cell death after day 5	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectInduction of IFN-Gamma, IL6 and other immunostimulatory cytokines production	Clinical trialNA	PMIDUS7473418